secondary hyperparathyroidism
hyperparathyroidismus secundarius latin

Chronic renal failure is the most common cause of secondary hyperparathyroidism.

Achieving therapeutic targets in the treatment of secondary hyperparathyroidism.

Secondary hyperparathyroidism occurs normally in patients that suffer renal disease.

Both processes lead to hypocalcemia and hence secondary hyperparathyroidism.

Doxercalciferol (trade name Hectorol) is drug for secondary hyperparathyroidism and metabolic bone disease.

This contrasts with secondary hyperparathyroidism, in which serum phosphate levels are generally elevated because of renal disease.

It is differentiated from primary hyperparathyroidism by a history of chronic kidney failure and secondary hyperparathyroidism.

Secondary hyperparathyroidism due to inadequate absorption of calcium may occur for GBP patients.

Signs and symptoms include ectopic calcification, secondary hyperparathyroidism, and renal osteodystrophy.

Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure.

Cinacalcet is used to treat secondary hyperparathyroidism (elevated parathyroid hormone levels), a consequence of having end-stage renal disease.

Renal disease (secondary hyperparathyroidism)

No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism.

Low vitamin D in the body can lead to a lack of calcium absorption and secondary hyperparathyroidism (hypocalcemia and raised parathyroid hormone).

Later this progresses to secondary hyperparathyroidism, renal osteodystrophy and vascular calcification that further impairs cardiac function.

When secondary hyperparathyroidism is corrected and the parathyroid glands remain hyperfunctioning, it becomes tertiary hyperparathyroidism.

Newer medications termed "calcimimetics" used in secondary hyperparathyroidism are now being used in Primary hyperparathyroidism.

Another related condition is called secondary hyperparathyroidism, or secondary HPT - common in patients with chronic kidney disease on dialysis.

Secondary hyperparathyroidism in severe chronic renal failure is corrected by very-low dietary phosphate intake and calcium carbonate supplementation.

"Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor and cyclin-dependent kinase inhibitors, p21 and p27."

Cinacalcet has greatly reduced the number of patients who ultimately require surgery for secondary hyperparathyroidism; however, approximately 5% of patients do not respond to medical therapy.

Metabolic bone disease manifesting as osteopenia and secondary hyperparathyroidism have been reported after Roux-en-Y gastric bypass surgery due to reduced calcium absorption.

Cinacalcet is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and hypercalcemia in patients with parathyroid carcinoma.

Tertiary hyperparathyroidism is developed when the hyperplastic gland constantly releases PTH after the secondary hyperparathyroidism independent to the regulation systems.

Doxercalciferol is used to reduce elevated intact parathyroid hormone (iPTH) levels in the treatment of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.